THURS-036 - Bridging the Gap in Pharmacoequity: Prescription and Utilization of Novel Type II Diabetes Medications
Thursday, April 17, 2025
11:45 AM – 12:45 PM PST
Location: Pacific I/II, 2nd Floor
Area of Responsibility: Area V: Advocacy Subcompetencies: 4.3.6 Analyze data., 4.4.6 Synthesize findings. 4.4.7 Develop recommendations based on findings. Research or Practice: Research
Social Science Researcher Stanford School of Medicine Novato, California, United States
Learning Objectives:
At the end of this session, participants will be able to:
Describe the patterns of prescription of novel diabetes drugs and identify differences in age, sex, race, and education between those prescribed SGLT2i's compared to those that were not.
Define pharmacoequity and describe the importance of advocating for it and its significance in vulnerable populations disparaged by health disparities
Define SGLT2 Inhibitors, their utilization as anti-diabetes drugs with cardiorenal protective effects, and disparities in their prescription
Brief Abstract Summary: 1. Gain insight into Pharmacoequity and the gap that exacerbates health disparities in underserved communities impacted by chronic disease 2. Learn about the impact of novel anti-diabetes medications and recognize the importance of equitable access 3. Learn about the variables (Age, Sex, race, among many others) that are associated with the rate of prescription of these medications 4. Discover the extent of the disparities that exist in the rate(s) of prescription of the anti-diabetes drugs, Sodium-Glucose Cotransporter II Inhibitors (SGLT2i) 5. Hear about recommendations to close this gap in pahramcoequity
Detailed abstract description: Pharmacoequity, a branch of health equity, is a fundamentally overlooked, but yet vital factor in addressing health disparities and the social justice of health access for all. The more aware communities and their leaders are of current research in pharmacoequity and recommendations, the more empowering this will be for all, including all health and medical practitioners, researchers, and educators. This knowledge will also inform and equip practitioners and educators with actionable items that can be implemented in their research, work, and/or education.
This presentation delves into the association of novel diabetes drug prescriptions with race and ethnicity, emphasizing the paramount importance of pharmacoequity. Using the findings from this study conducted at Joslin Diabetes Center at Harvard School of Medicine, the presentation will demonstrate to attendees the importance of advocating for pharmacoequity, its significance in vulnerable populations diagnosed with diabetes, and recommendations. The findings underscore the need for more studies exploring pharmacoequity in various chronic diseases to address health disparities comprehensively.
For these reasons, our team passionately believes that SOPHE conference attendees would find great interest and value in our presentation. The first step to any change is awareness and we believe that this study and presentation parallel SOPHE’s interest in and commitment to health equity and social justice. While I am a member of the American Diabetes Association and NCHEC as a certified health education specialist, I am currently not a member of SOPHE, however, I humbly request that SOPHE consider our abstract for presentation given its tailored nature in health equity, health disparities, and social justice amidst the growing epidemic of Type 2 Diabetes.
